Jaren Madden joined Gamida Cell’s leadership team as vice president, investor relations and corporate communications in July 2018, bringing nearly 20 years of experience in strategic communications and investor relations in the biotechnology and pharmaceutical industries. Jaren joined Gamida Cell from Shire plc, where, as the global head of research and development (R&D) communications, she set strategy and execution of R&D communications plans for approximately 20 preclinical and clinical programs. Prior to joining Shire, Jaren served in roles of increasing responsibility at Infinity Pharmaceuticals, Inc., most recently as senior director, investor relations and corporate communications, where she developed the strategy for and oversaw the execution of corporate communications initiatives and served as the primary company interface to investors and media. While at Infinity, Jaren worked with the management team on multiple equity offerings, raising total net proceeds over $240 million. Before joining Infinity, Jaren held roles of increasing responsibility at Feinstein Kean Healthcare, Alkermes plc and Vertex Pharmaceuticals, Inc.
Jaren holds a B.S. in ecology and evolutionary biology and an M.S. in botany from UConn, and an MBA from Boston University.